NCT02448303View on ClinicalTrials.gov

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2018

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Pembrolizumab

DRUG

Acalabrutinib

Trial Locations (1)

85338

Western Regional Medical Center/Cancer Treatment Center of America, Goodyear

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY